Gefitinib (Iressa), a tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) for treatment of non-small cell lung cancer (NSCLC) [23, 24], was used as a model drug in the study. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.